Cavion, Inc. started off 2017 with a bang by announcing a $26.1 million venturing financing with Lilly Ventures, Novartis Venture Fund and Enso Ventures. The funding will be used to continue Cavion’s development of T-type calcium channel modulators for neurological and rare genetic diseases. For more details see the full press release link below.
“We welcome the backing of Novartis Venture Fund, Lilly Ventures, and Enso. They bring a superior track record of success stemming from their deep pharmaceutical industry experience and understanding of the biotech marketplace.” – Andrew Krouse, President and CEO of Cavion